Stifel Financial Corp Sells 4,735 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Stifel Financial Corp cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,491 shares of the biopharmaceutical company’s stock after selling 4,735 shares during the quarter. Stifel Financial Corp owned 0.22% of Dynavax Technologies worth $3,180,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,685 shares during the last quarter. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of Dynavax Technologies during the 3rd quarter valued at about $45,000. Nisa Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the period. Finally, Centiva Capital LP purchased a new position in shares of Dynavax Technologies in the third quarter worth approximately $119,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.90 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a 50-day simple moving average of $12.06 and a two-hundred day simple moving average of $11.49. The firm has a market capitalization of $1.70 billion, a PE ratio of 99.23 and a beta of 1.33. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.